BLOG

Bay Area Biotech Company Takes New Approach in COVID-19 Treatment

A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports.